Karex management literally said a few months ago that "the worst is over". If the next quarter is as bad as you claim, then that means Karex management and The Edge was lying to investors.
OMG!!! I FORGOT I had bought back the Karex shares I SOLD @ high prices way back in 2H 2020 last year....just checked my records...I averaged down 43k since 2021 fr 48c down to 41c! =)
Key Catalysts for Traders and Investors: 1. US Supreme Court decision Roe v Wade to spur an uptick in condom usage (NA and EMEA region) 2. Recent fall of freight rates as well as raw material costs such as rubber and silicone oil (been a major concern due to supply chain issues since Q2 FY20). This will greatly reduce distribution expenses, manufacturing costs. Likely to contribute towards at least ~8% of their net profits in FY23 3. Consolidation of major industry players such as Reckitt Benkinser and more to contribute towards market share growth for Karex 4. High management confidence as reflected in previous briefing and earning calls. The chairman is very confident about the company outlook moving forward. Utilization rate has already improved signficantly 5. The company is actively putting CAPEX into improving production capacity for other alternative products apart from its core product. (The Edge: The planned RM40 million glove manufacturing facility was announced in August 2020, during the height of the Covid-19 pandemic. The factory is located in Hatyai, Thailand, with a planned capacity of up to 2.5 billion pieces annually.) 6. No need to raise equity or share issuance to pay debt. Cash position looks good and balance sheet remains healthy despite heavy investments. 7. Strong macroeconomic support. The healthcare sector is generally resistant against any form of economic downturn.
This will be another high conviction play like Kawan Food. No short-term trade for me, at least 6 month hold
Quarterly out reporting record revenue and they managed to eek out a profit. Perhaps the tide is slowly turning with this company. Distribution costs are still a concern (to me anyway), so if they are able to drill down in some way with those costs it will be a positive advantage to the bottom line.
Re Distribution costs, this quarter's gross profit was Rm34.2 Million and Distribution costs of Rm16 Million to be taken out of the GP. The previous quarter the GP was Rm22.4 million with Distribution costs of Rm10.3 Million. So in percentage terms, they haven't been able yet to put a major dent in their distribution. costs. If they are able to address this issue and revenue can be consistent then there might be a chance for this company to get some traction.
As always, Karex are light on information in their quarterlies about the commencement of their glove factory in Thailand, something they really need to sort out to keep shareholders a lot more up to date and in the loop. I'm still assuming that it is meant to be operational in Q1 2023.
For holders I'd say this quarterly would be seen as a positive, especially when you consider the last few years during Covid. Perhaps an eventual turnaround story.
Just letting you all know that my old account (wallstreetrookie) was banned by i3investor forum admin. I am not kidding. What a bunch of aholes. Now I am lazy to do research and share on forums anymore. Not worth my time and energy. No one paid me a single cent, and I still get banned on i3 forum for sharing ideas.
I cannot even comment using my wallstreetrookie account anymore. It's forever gone. Banned by admin. I don't even make money from sharing ideas and they still wanna ban me. Legend.
Don't cry. You haven't faced a tad bit what I got. Just move on, there is no justice in i3 and all your wallowing will fall on deaf ears or rather eyes.
Key Catalysts for Traders and Investors: 1. US Supreme Court decision Roe v Wade to spur an uptick in condom usage (NA and EMEA region) 2. Recent fall of freight rates as well as raw material costs such as rubber and silicone oil (been a major concern due to supply chain issues since Q2 FY20). This will greatly reduce distribution expenses, manufacturing costs. Likely to contribute towards at least ~8% of their net profits in FY23 3. Consolidation of major industry players such as Reckitt Benkinser and more to contribute towards market share growth for Karex 4. High management confidence as reflected in previous briefing and earning calls. The chairman is very confident about the company outlook moving forward. Utilization rate has already improved signficantly 5. The company is actively putting CAPEX into improving production capacity for other alternative products apart from its core product. (The Edge: The planned RM40 million glove manufacturing facility was announced in August 2020, during the height of the Covid-19 pandemic. The factory is located in Hatyai, Thailand, with a planned capacity of up to 2.5 billion pieces annually.) 6. No need to raise equity or share issuance to pay debt. Cash position looks good and balance sheet remains healthy despite heavy investments. 7. Strong macroeconomic support. The healthcare sector is generally resistant against any form of economic downturn.
This will be another high conviction play like Kawan Food. No short-term trade for me, at least 6 month hold
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
wallstreetrookie
9,784 posts
Posted by wallstreetrookie > 2022-11-10 16:10 | Report Abuse
Nice, I just lost RM10k in 1 hour